Product details

Share this page:
Please find below the full details of the product you clicked a link to view.
Published by:
Amity Research Centers (2016)
10 pages
Data source:
Published sources
This item is part of a free case collection. For terms & conditions go to


Ever since the time nanotechnology came into existence, there had been a lot of brainstorming on its economic prospects as well as the underlying challenges regarding its practicability especially in the field of medicine. All these facilitated the province of nanomedicine to offer bigger promises and even bigger debates surrounding its viability. In late 2015, the US Hospital Cleveland Clinic and the Hebrew University of Jerusalem joined hands towards a virtual partnership. The intended outcome was to float and develop the global Centre for Transformative Nanomedicine. Both the partners were globally renowned biomedical research institutions, and their virtual partnership was expected to strengthen development of nanotechnological techniques and commercialise the same so as to ease out diagnosis as well as treatment of diseases like cancer, cardiovascular diseases and so on. As expected, the collaboration all over again came with a lot more promises as well as a bigger scope for debate as to whether the two institutions could succeed in developing and commercialising nanomedicine to ultimately redefine things in the realm of diagnostics and treatment. What would ultimately determine the chances of success of this virtual partnership between the two institutions that were benchmarked against the best in their respective domains in a strongly debated field remained a question to brood over. This case is part of the Amity Research Centers free case collection (visit for more information on the collection).


Virtual partnership; Inter-institutional collaborations; Financial profitability; Commercialisation for nanotechnology
Other setting(s):

Access this item
View our pricing guide
or to see prices.

Reviews & usage